A measles-vectored vaccine candidate expressing prefusion-stabilized SARS-CoV-2 spike protein brought to phase I/II clinical trials: protection of African green monkeys from COVID-19 disease.
Nambulli S, Escriou N, Rennick LJ, Demers MJ, Tilston-Lunel NL, McElroy AK, Barbeau DJ, Crossland NA, Hoehl RM, Schrauf S, White AG, Borish HJ, Tomko JA, Frye LJ, Scanga CA, Flynn JL, Martin A, Gerke C, Hartman AL, Duprex WP.
Nambulli S, et al. Among authors: demers mj.
J Virol. 2024 May 14;98(5):e0176223. doi: 10.1128/jvi.01762-23. Epub 2024 Apr 2.
J Virol. 2024.
PMID: 38563762
Free PMC article.